Oct 25, 2017

Castlight Health Announces Third Quarter 2017 Results

Total Revenue of $34.6 million, Up 36% Year-over-Year

SAN FRANCISCO October 25, 2017 – Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its third quarter ended September 30, 2017.

“We are encouraged by our second consecutive quarter of solid financial performance after closing the Jiff acquisition, with new business momentum, continued operating efficiencies and a broadening product footprint across our customer base,” said John Doyle, chief executive officer of Castlight Health. “With our comprehensive platform that simplifies healthcare navigation, we believe we help employers achieve more with their benefits spending and help their employees lead healthier, happier, and more productive lives.”

Financial performance for the three months ended September 30, 2017 compared to the three months ended September 30, 2016:

  • Total revenue of $34.6 million, an increase of 36%
  • Subscription revenue of $31.4 million, an increase of 31%
  • Gross margin of 62.3%, compared to 68.8%
  • Non-GAAP gross margin of 66.9% compared to 72.1%
  • Operating loss of $18.6 million, compared to a loss of $11.5 million
  • Non-GAAP operating loss of $6.6 million, compared to a loss of $5.5 million
  • Net loss per diluted share of $0.14, compared to a net loss per diluted share of $0.11
  • Non-GAAP net loss per diluted share of $0.05, compared to a net loss per diluted share of $0.05
  • Cash used in operations of $8.4 million, compared to $9.4 million used in operations

Total cash, cash equivalents and marketable securities was $87.1 million as of September 30, 2017.

The financial performance of Jiff, Inc., which Castlight acquired on April 3, 2017, is not included in the year-ago period metrics. A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

 

Board of Directors Changes

Castlight Health today also announced changes to its board of directors. Castlight co-founder and executive chairperson Dr. Giovanni M. Colella and Jiff, Inc. co-founder Mr. James Currier, have stepped down from the Castlight board, effective today. Dr. Bryan Roberts, currently serving as lead independent director, assumed the chairperson role which he previously held from 2010 to April 2017. Additionally, Mr. Seth Cohen, an experienced senior sales leader at Castlight, will be joining the board, effective January 1, 2018.

“We would like to thank Gio and James for helping create two of the most revolutionary and successful companies in digital health that, combined, simplify healthcare for both employers and their employees. The board and the Castlight team are indebted to Gio and James for their vision, leadership and valuable contributions, and I would like to thank Gio personally for his mentorship over the years.” said John Doyle, chief executive officer of Castlight Health. “The board and I look forward to working with Seth, who brings a valuable, customer-centric perspective to our board that I believe will help us accelerate the adoption of our health navigation platform.”

“With Castlight’s increased focus on execution across its go-to-market, product integration and sustainability initiatives, James and I concluded it is the right time to step down from the board,” said Dr. Giovanni M. Colella. “We are incredibly proud of the Castlight family and believe the company, under its excellent leadership from John and Derek, is in a strong position to deliver on its strategy. James and I wish the entire Castlight team continued success.”

 

About Seth Cohen

A sales leader with the company since November 2010, Mr. Cohen is currently Castlight’s vice president, sales and alliances, and has extensive experience in digital healthcare go-to-market execution. Prior to joining Castlight, Mr. Cohen was a consultant for McKinsey & Company as a member of their healthcare payer and provider practice, and an adjudicator for the Beacon Community Grant program within the U.S. Department of Health and Human Services. Mr. Cohen holds a MBA from the Harvard Business School, an MPH from the Harvard Kennedy School, and a BA in International Relations from Stanford University.

 

Business Outlook

For the full year 2017, the Company expects GAAP revenue to be above $130 million. Based on operating expense synergies, Castlight expects to beat its previously-issued full year 2017 non-GAAP operating loss guidance range of $31 to $35 million. The company also expects to beat its previously-issued full year 2017 non-GAAP net loss per share guidance range of approximately $0.24 to $0.28, based on approximately 125 to 127 million shares. Non-GAAP guidance metrics exclude the effects of stock-based compensation, amortization of intangibles, capitalization and amortization of internal-use software, changes in fair value of contingent consideration, and charges related to the acquisition.

 

Quarterly Conference Call

Castlight Health senior management will host a conference call to discuss its third quarter 2017 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (866) 393-4306. The conference ID number is 93260120. A replay will be available for one week at (855) 859-2056, passcode 93260120.

Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating loss and non-GAAP net loss exclude stock-based compensation, litigation settlement, charges related to a reduction in workforce, amortization of intangibles, capitalization and amortization of internal-use software, changes in fair value of contingent consideration and charges related to the acquisition and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2017 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense, capitalization and amortization of internal-use software, changes in fair value of contingent consideration and charges related to the acquisition, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software and charges related to the proposed acquisition for the year.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s 2017 full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2017 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

As of

September
30, 2017

December
31, 2016

 (unaudited)

Assets

Current assets:

Cash and cash equivalents

$

44,986

$

48,722

Marketable securities

42,074

65,882

Accounts receivable, net

26,017

14,806

Deferred commissions

7,805

8,218

Prepaid expenses and other current assets

5,712

3,382

Total current assets

126,594

141,010

Property and equipment, net

5,670

5,285

Restricted cash, non-current

1,325

1,144

Goodwill

91,785

Intangible assets, net

21,469

Deferred commissions, non-current

4,021

5,050

Other assets

7,338

4,677

Total assets

$

258,202

$

157,166

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

3,393

$

2,288

Accrued expenses and other current liabilities

14,615

6,369

Accrued compensation

12,151

9,443

Deferred revenue

34,974

30,623

Total current liabilities

65,133

48,723

Deferred revenue, non-current

8,412

5,245

Debt, non-current

5,423

Other liabilities, non-current

1,955

1,236

Total liabilities

80,923

55,204

Commitments and contingencies

Stockholders’ equity:

Class A and Class B common stock

13

10

Additional paid-in capital

580,282

457,596

Accumulated other comprehensive loss

(5)

Accumulated deficit

(403,011)

(355,644)

Total stockholders’ equity

177,279

101,962

Total liabilities and stockholders’ equity

$

258,202

$

157,166

 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2017

2016

2017

2016

Revenue:

Subscription

$

31,363

$

23,867

$

86,963

$

66,859

Professional services and other

3,209

1,634

7,453

4,944

Total revenue, net

34,572

25,501

94,416

71,803

Cost of revenue:

Cost of subscription (1)

8,123

3,988

20,075

12,218

Cost of professional services and other (1)

4,898

3,978

13,679

13,941

Total cost of revenue

13,021

7,966

33,754

26,159

Gross profit

21,551

17,535

60,662

45,644

Operating expenses:

Sales and marketing (1)

16,006

13,143

47,024

44,877

Research and development (1)

13,809

10,573

40,074

30,619

General and administrative (1)

10,307

5,338

26,071

19,902

Total operating expenses

40,122

29,054

113,169

95,398

Operating loss

(18,571)

(11,519)

(52,507)

(49,754)

Other income, net

84

116

288

304

Loss before income tax benefit

$

(18,487)

(11,403)

$

(52,219)

(49,450)

Income tax benefit

5,206

Net loss

$

(18,487)

$

(11,403)

$

(47,013)

$

(49,450)

Net loss per Class A and B share, basic and diluted

$

(0.14)

$

(0.11)

$

(0.38)

$

(0.50)

Weighted-average shares used to compute basic and diluted net loss per Class A and B share

132,251

103,147

122,675

99,734

_______________________

(1)

Includes stock-based compensation expense as follows:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2017

2016

2017

2016

Cost of revenue:

Cost of subscription

$

258

$

139

$

638

$

367

Cost of professional services and other

342

456

1,400

1,468

Sales and marketing

3,110

2,190

7,705

6,644

Research and development

1,631

1,631

5,675

4,300

General and administrative

1,121

1,236

3,586

3,476

 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

Three Months Ended

Nine Months Ended

September
30, 2017

September
30, 2016

September
30, 2017

September
30, 2016

Operating activities:

Net loss

$

(18,487)

$

(11,403)

$

(47,013)

$

(49,450)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

1,814

822

4,572

2,407

Stock-based compensation

6,463

5,652

19,004

16,255

Amortization of deferred commissions

2,950

1,042

8,120

3,157

Release of deferred tax valuation allowance due to business combination

(5,206)

Change in fair value of contingent consideration liability

3,931

3,288

Accretion and amortization of marketable securities

(64)

101

22

406

Changes in operating assets and liabilities:

Accounts receivable

(4,661)

(3,397)

(7,778)

(3,137)

Deferred commissions

(3,280)

(1,479)

(6,678)

(4,403)

Prepaid expenses and other assets

467

745

(393)

(68)

Accounts payable

909

410

401

300

Accrued expenses and other liabilities

3,148

(3,583)

2,623

(4,046)

Deferred revenue

(1,541)

1,733

5,661

3,318

Net cash used in operating activities

(8,351)

(9,357)

(23,377)

(35,261)

Investing activities:

Restricted cash

181

(181)

Purchase of property and equipment

(1,345)

(345)

(2,276)

(1,587)

Purchase of marketable securities

(25,077)

(11,971)

(56,852)

(73,163)

Maturities of marketable securities

16,896

35,570

80,633

126,157

Business combination, net of cash acquired

(2,264)

Net cash provided by (used in) investing activities

(9,345)

23,254

19,060

51,407

Financing activities:

Proceeds from the exercise of stock options

481

636

1,312

2,576

Proceeds from issuance of common stock and warrants

17,358

Payments of issuance costs related to equity

(76)

(731)

(122)

Net cash provided by financing activities

481

560

581

19,812

Net (decrease) increase in cash and cash equivalents

(17,215)

14,457

(3,736)

35,958

Cash and cash equivalents at beginning of period

62,201

40,651

48,722

19,150

Cash and cash equivalents at end of period

$

44,986

$

55,108

$

44,986

$

55,108

Non-cash investing and financing activity:

Non-cash purchase consideration related to acquisition of Jiff

$

$

$

101,692

$

 

CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Three Months Ended

Nine Months Ended

September
30,

June 30,

September
30,

September
30,

September
30,

2017

2017

2016

2017

2016

Gross profit:

GAAP gross profit subscription

$

23,240

$

22,128

$

19,879

$

66,888

$

54,641

Stock-based compensation

258

253

139

638

367

Amortization of internal-use software

244

244

244

732

732

Amortization of intangibles

751

751

1,502

Reduction in workforce

5

Acquisition related costs

52

52

Non-GAAP gross profit subscription

$

24,493

$

23,428

$

20,262

$

69,812

$

55,745

GAAP gross margin subscription

74.1%

74.2%

83.3%

76.9%

81.7%

Non-GAAP gross margin subscription

78.1%

78.5%

84.9%

80.3%

83.4%

GAAP gross loss professional services

$

(1,689)

$

(2,528)

$

(2,344)

$

(6,226)

$

(8,997)

Stock-based compensation

342

597

456

1,400

1,468

Reduction in workforce

4

103

Acquisition related costs

(4)

17

160

Non-GAAP gross loss professional services

$

(1,351)

$

(1,914)

$

(1,884)

$

(4,666)

$

(7,426)

GAAP gross margin professional services

(53)%

(112)%

(143)%

(84)%

(182)%

Non-GAAP gross margin professional services

(42)%

(85)%

(115)%

(63)%

(150)%

GAAP gross profit

$

21,551

$

19,600

$

17,535

$

60,662

$

45,644

Impact of non-GAAP adjustments

1,591

1,914

843

4,484

2,675

Non-GAAP gross profit

$

23,142

$

21,514

$

18,378

$

65,146

$

48,319

GAAP gross margin

62.3%

61.1%

68.8%

64.2%

63.6%

Non-GAAP gross margin

66.9%

67.0%

72.1%

69.0%

67.3%

Operating expense:

GAAP sales and marketing

$

16,006

$

16,575

$

13,143

$

47,024

$

44,877

Stock-based compensation

(3,110)

(2,441)

(2,190)

(7,705)

(6,644)

Amortization of intangibles

(448)

(448)

(896)

Reduction in workforce

(48)

(422)

Acquisition related costs

14

(518)

(909)

Non-GAAP sales and marketing

$

12,462

$

13,168

$

10,905

$

37,514

$

37,811

GAAP research and development

$

13,809

$

15,194

$

10,573

$

40,074

$

30,619

Stock-based compensation

(1,631)

(2,254)

(1,631)

(5,675)

(4,300)

Capitalization of internal-use software

Reduction in workforce

(18)

(136)

Acquisition related costs

(126)

(393)

Non-GAAP research and development

$

12,178

$

12,814

$

8,924

$

34,006

$

26,183

GAAP general and administrative

$

10,307

$

6,766

$

5,338

$

26,071

$

19,902

Stock-based compensation

(1,121)

(1,169)

(1,236)

(3,586)

(3,476)

Litigation settlement

(250)

(2,876)

Amortization of intangibles

(17)

(17)

(34)

Change in fair value of contingent consideration liability

(3,931)

643

(3,288)

Reduction in workforce

(10)

(90)

Acquisition related costs

(126)

(899)

(3,365)

Non-GAAP general and administrative

$

5,112

$

5,324

$

4,092

$

15,548

$

13,460

GAAP operating expense

$

40,122

$

38,535

$

29,054

$

113,169

$

95,398

Impact of non-GAAP adjustments

(10,370)

(7,229)

(5,133)

(26,101)

(17,944)

Non-GAAP operating expense

$

29,752

$

31,306

$

23,921

$

87,068

$

77,454

Operating loss:

GAAP operating loss

$

(18,571)

$

(18,935)

$

(11,519)

$

(52,507)

$

(49,754)

Impact of non-GAAP adjustments

11,961

9,143

5,976

30,585

20,619

Non-GAAP operating loss

$

(6,610)

$

(9,792)

$

(5,543)

$

(21,922)

$

(29,135)

Net loss and net loss per share:

GAAP net loss

$

(18,487)

$

(13,717)

$

(11,403)

$

(47,013)

$

(49,450)

Total pre-tax impact of non-GAAP adjustments

11,961

9,143

5,976

30,585

20,619

Release of deferred tax valuation allowance due to business combination

(5,206)

(5,206)

Income tax impact of non-GAAP adjustments

Non-GAAP net loss

$

(6,526)

$

(9,780)

$

(5,427)

$

(21,634)

$

(28,831)

GAAP net loss per share, basic and diluted

$

(0.14)

$

(0.11)

$

(0.11)

$

(0.38)

$

(0.50)

Non-GAAP net loss per share, basic and diluted

$

(0.05)

$

(0.07)

$

(0.05)

$

(0.18)

$

(0.29)

Shares used in basic and diluted net loss per share computation

132,251

130,537

103,147

122,675

99,734

 

Castlight Media Contact:
Shannon Magill
[email protected]
415-829-1500

Castlight Investor Contact:
Gary J. Fuges, CFA
[email protected]
415-829-1680

Press Information